Brian Bloom is a co-founder of Bloom Burton & Co. and serves as the firm's President and Head of Institutional Sales and capital market activities. By forging unique relationships with international healthcare-specialized investors, Brian attracts capital for growing companies seeking to accelerate returns for investors.
Before co-founding Bloom Buton, Brian spent six years at Dundee Securities in the Healthcare and Biotechnology Institutional Sales and Equity Research groups. Earlier in his career, he spent two years in the equity research group at a New York-based merchant banking firm, SCO Group, and was an investment banking analyst at M&A advisory firm, Molecular Securities.
Brian is a member of the Life Sciences Advisory Board at the National Research Council of Canada and the Board of Directors at BIOTECanada. Brian also serves on the Board of Directors at the Baycrest Foundation and the Advisory Board of the Cell Therapy Program at Princess Margaret Hospital.
Brian received Honors Bachelor of Science in Biochemistry from McMaster University and subsequently studied at the Mount Sinai Graduate School for Biological Sciences of New York University with a focus in molecular endocrinology and biophysics.